TriSalus Life Sciences today announced positive clinical results for its Pressure-Enabled Regional Immuno-Oncology technology. The company, currently in the process of going public through a SPAC merger, filed a presentation for investors. It features information regarding its ongoing PERIO 01 and PERIO 02 clinical studies. The studies evaluate the TriNav pressure-enabled drug delivery technology for […]
trisaluslifesciences
TriSalus enrolls first patient in pressure-enabled drug delivery trial for treating melanoma
TriSalus Life Sciences announced today that it enrolled the first patient in its clinical study of a treatment for metastatic uveal melanoma. The PERIO-01 clinical study evaluates SD-101, an investigational toll-like receptor 9 (TLR9) agonist in adults with metastatic uveal melanoma through intravascular administration into uveal melanoma liver metastasis lesions in combination with checkpoint inhibitors using […]
TriSalus, University of Texas to collaborate on solid tumor treatment study
TriSalus Life Sciences and the University of Texas today announced a collaboration to evaluate the treatment of solid tumors. The Texas MD Anderson Cancer Center and TriSalus will collaborate on treatments for tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint inhibition […]
TriSalus names new chief medical officer
TriSalus today said it appointed Steven Katz as chief medical officer. Katz will be responsible for overseeing the company’s clinical development strategy in the treatment of solid tumors. He has served as TriSalus’s chief medical advisor and chairperson of its scientific advisory board since 2018. “We are thrilled to have Steven join TriSalus as a […]
TriSalus appoints chief financial officer
TriSalus today said it appointed Scott Davie as chief financial officer. Davie will be responsible for overseeing research and development of the company’s intravascular infusion systems. He will report directly to president and CEO Mary Szela. “We’re thrilled to add Scott’s deep experience in medical device development and commercialization to the critical work underway at […]
TriSalus appoints chief financial officer
TriSalus this week said it appointed Rajesh Mistry as chief financial officer. Mistry brings more than 15 years of experience to the company. He most recently served as head of corporate development at Option Care Health. He has also held numerous leadership positions at Melinta Therapeutics, Baxter International and A.G. Edwards Capital Markets. “We are […]
TriSalus launches TriNac Infusion System
TriSalus this week launched its TriNac Infusion System. The infusion system is powered by the company’s Pressure-Enabled Drug Delivery (PEDD) approach with SmartValve technology and is designed to help with the infusion barriers that can limit therapeutic uptake in solid tumors. It gives interventional radiologists intravascular tumor access and improved traceability, compatibility with standard angiographic catheters. […]
TriSalus touts data for pressure-enabled drug-delivery tech
TriSalus Life Sciences touted results today from a Phase Ib trial of its pressure-enabled drug-delivery tech for immunotherapy. The company reported that delivering a concentrated dose of CAR-T cells at the site of a solid tumor using its technology was safe and contributed to positive clinical results. Get the full story at our sister site, Drug […]
GE replaces CEO Flannery with ex-Danaher chief Culp | Personnel Moves – October 1, 2018
General Electric (NYSE:GE) said today it named former Danaher (NYSE:DHR) prez and CEO H. Lawrence Culp Jr. as its chair and CEO, replacing John Flannery, effective immediately. The Boston-based company said that alongside the switch in the corner office, it does not expect it will meet its guidance for free cash flow and earnings per share for […]